Clinical trials: Buprenorphine
Hepatitis C, Chronic, Substance Abuse Treatment Centers
Hepatitis C Among Opioid Addicts in Opioid Maintenance Treatment in Zurich, Switzerland
Hepatitis C viral infection is common among opioid addicts in Zurich, Switzerland. The majority undergoes a maintenance treatment with methadone, heroin or buprenorphine.
- Conditions
- Hepatitis C, Chronic, Substance Abuse Treatment Centers, Opioid-Related Disorders
- Trial name
- HepCOP (NCT00473993)
- Sponsor
- Seidenberg, Arztpraxis A., M.D.
Opioid Use Disorder
Reward-Based Recovery Outcomes Management for Opioid Use Disorder
A randomized pilot study assessing feasibility, acceptability, and preliminary effectiveness of a reward-based recovery management platform (PROCare) designed to enhance participation in outcomes monitoring, engagement in…
- Trial name
- NCT04669249
- Testing
- PROCare
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Medical Decision Logic, Inc.
Opioid Use Disorder, Posttraumatic Stress Disorder
Novel Telemedicine-Delivered Prolonged Exposure Therapy for Treating PTSD in Individuals With OUD
Among individuals with opioid use disorder (OUD), posttraumatic stress disorder (PTSD) presents a significant clinical challenge.
- Trial name
- NCT06288711
- Testing
- Prolonged exposure therapy, Financial incentives, Treatment as usual
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- University of Vermont
Opioid Dependence
Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in Norway
Persons dependent on opioids like heroin, morphine, or codeine have a high risk of relapse, overdose and overdose death. This risk is elevated even further following discharge from treatment or correctional institutions where…
- Trial name
- NTX-SBX (NCT01717963)
- Testing
- Naltrexone intramuscular suspension, Buprenorphine-naloxone
- Where
- 5 sites in Norway
- Volunteers
- 166 people
- Sponsor
- University of Oslo
Obesity, Morbid
Bariatric Surgery and Pharmacokinetics of Buprenorphine
Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines.
- Trial name
- NCT03460314
- Testing
- Buprenorphine
- Where
- Norway
- Volunteers
- 12 people
- Sponsor
- Norwegian University of Science and Technology
Opioid Use Disorder
Long Acting Subcutaneous vs Short Acting Sublingual Buprenorphine in Pregnant and Lactating Women
This is a non-inferiority, open label, randomized trial of women on buprenorphine Medication Assisted Therapy for opioid use disorder in pregnancy.Patients will be randomized to either the long acting monthly subcutaneous…
- Trial name
- NCT04212065
- Testing
- buprenorphine
- Where
- United States
- Sponsor
- Ohio State University
Heroin Dependence
Study Comparing Liquid and Tablet Buprenorphine Formulations - 5
The purpose of this study is to compare liquid and tablet buprenorphine formulations.
- Trial name
- NCT00000302
- Testing
- Buprenorphine
- Where
- United States
- Sponsor
- National Institute on Drug Abuse (NIDA)
Opioid Dependence
Extension to Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence
Buprenorphine (BPN) is an approved treatment for opioid dependence; however, in taking oral tablets, patients experience withdrawal and cravings when the variable BPN levels in the blood are low.
- Trial name
- PRO-807 (NCT00630201)
- Testing
- Probuphine (buprenorphine implant)
- Where
- 15 sites in United States
- Volunteers
- 62 people
- Sponsor
- Titan Pharmaceuticals
Opiate Addiction
Examination of Cognitive Function in Patients Treated With Subutex
People who addicted to Heroin and other opiates suffer from a disease with approved genetic basis. It causes to a behavioral response as searching and using those drugs even though they know it causes severe damages as…
- Trial name
- NCT00687089
- Testing
- Sexual, cognitive functional tests and measurement weight
- Volunteers
- 60 people
- Sponsor
- BeerYaakov Mental Health Center
Opioid Use Disorder
Acceptability and Feasibility of Extended-Release Subcutaneous Buprenorphine on a Mobile Pharmacy Clinic
This exploratory project will assess the acceptability and feasibility of monthly extended-release subcutaneous buprenorphine (BRIXADI; XR-B) to treat opioid use disorder (OUD) among persons in the community receiving care on a…
- Trial name
- NCT07176351
- Testing
- Buprenorphine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Yale University
Opioid-Related Disorders
Buprenorphine Detoxification - BBDVI - 19
The purpose of this study is to examine the long-term efficacy of alternate-day dosing schedules in promoting treatment compliance in the absence of confounding behavioral contingencies.
- Trial name
- NCT00000237
- Testing
- Buprenorphine
- Where
- United States
- Sponsor
- National Institute on Drug Abuse (NIDA)
Sickle Cell Disease
Assessing the Safety of Buprenorphine in People With Sickle Cell Disease
This study will assess the safety of changing pain medications (opioids) adult sickle cell patients take to another type of medication therapy (buprenorphine). Patients will be asked questions about their quality of life.
- Trial name
- NCT03492099
- Testing
- buprenorphine
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Johns Hopkins University
Spinal Stenosis, Pain, Postoperative
Postoperative Analgesia With Buprenorphine for Postoperative Pain Control and Quality of Life After Spinal Surgery
Major purpose of this research is to evaluate the effect and usefulness of Buprenorphine transdermal system (MTDS) among the patients with lumbar spinal disease who was performed the single-level posterior lumbar fusion.
- Trial name
- NCT02416804
- Testing
- Buprenorphine, Tramadol
- Where
- South Korea
- Volunteers
- 69 people
- Sponsor
- Seoul National University Hospital
Opioid-use Disorder
Medication Maintenance Therapy in Community Pharmacy Settings
The goal of this study is to examine how the pharmacy can better optimize treatment expansion by providing pharmacy-based medication assisted treatment (MAT) for maintenance under a collaborative pharmacy practice agreement.
- Trial name
- MATPharm (NCT03766893)
- Testing
- Buprenorphine / Naloxone Oral Product, injectable naltrexone, Pharmacy maintenance addiction care
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Lifespan
Drug Addiction
Survey of Buprenorphine Use Among "Out of Care" Population in France (P04933)(COMPLETED)
This study was a survey of drug users who obtain buprenorphine from the black market and have used buprenorphine during the last month.
- Trial name
- NCT00756353
- Volunteers
- 600 people
- Sponsor
- Indivior Inc.
Heroin Dependence, Opioid-Related Disorders
Sustained Release d-Amphetamine & Buprenorphine on Drug Seeking Behavior in Opioid & Cocaine Dependent Individuals
The purpose of this study is to determine whether maintenance on different oral doses of sustained release d-amphetamine (SR-AMP) combined with constant-dose sublingual buprenorphine (BUP) is safe and well tolerated and decreases…
- Conditions
- Heroin Dependence, Opioid-Related Disorders, Cocaine Abuse or Dependence
- Trial name
- NCT00429767
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Wayne State University
Opioid-Related Disorders
Alternate Day Buprenorphine Administration, Phase XII - 17
The purpose of this study is to determine if six times daily buprenorphine dose is effective in achieving 120 hour buprenorphine dosing.
- Trial name
- NCT00000235
- Testing
- Buprenorphine
- Where
- United States
- Sponsor
- National Institute on Drug Abuse (NIDA)
Cancer Pain
A Study to Evaluate Buprenorphine Transdermal Patch in Chinese Subjects With Moderate to Severe Chronic Cancer Pain
This is a randomised, active-controlled, double-blind, double-dummy, parallel group study with BUP TDS 20 mg (release rate 35 µg/h), 30 mg (release rate 52.5 µg/h) and 40 mg (release rate 70 µg/h), and MOR SR 60 mg, 100 mg or 120…
- Trial name
- NCT03967327
- Testing
- Buprenorphine transdermal patches, Morphine Sulfate Sustained-Release Tablet
- Where
- China
- Volunteers
- 194 people
- Sponsor
- Mundipharma (China) Pharmaceutical Co. Ltd
Opioid-related Disorders, Buprenorphine
Neurocognitive Effects of Buprenorphine Among HIV+ and HIV-Opioid Users
The purpose of this study is to examine how Buprenorphine, a form of opioid addiction treatment, changes the ability to think and reason among people addicted to opiates, who are either HIV negative or HIV positive.
- Conditions
- Opioid-related Disorders, Buprenorphine, HIV, Cognition
- Trial name
- NCT01108679
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Albert Einstein College of Medicine
Opioid-Related Disorders
Alternate-Day Buprenorphine Administration. Phase I - 3
The purpose of this study is to determine if two times a subject's daily maintenance dose will hold for 48 hours without changes in agonist and antagonist effects.
- Trial name
- NCT00000221
- Testing
- Buprenorphine
- Where
- United States
- Sponsor
- National Institute on Drug Abuse (NIDA)